Abivax annonce son intention de proceder a une offre au public aux Etats-Unis
Retrieved on:
Jeudi, août 10, 2023
The launch of the Phase 3 program follows the promising results obtained in the SARA-INT Phase 2b study, and the scientific advice given in 2022 by the EMA (European Medicine Agency), which helped define the conditions for starting such a study in Europe, specifying the Phase 3 protocol.